VTVT - vTv Therapeutics starts TTP399 diabetes study

vTv Therapeutics (VTVT) announces the initiation of a mechanistic study exploring the effects of TTP399 on ketone body formation during a period of insulin withdrawal in people with type 1 diabetes.Shares up more than 20% after market.The phase 1 study will test the hypothesis that treatment with vTv’s TTP399, a liver-selective glucokinase activator, will not result in the increased production of ketones, a precursor to ketoacidosis, which can lead to hospitalization in patients with type 1 diabetes.TTP399 previously showed improvement in glycemic control without increased incidence of diabetic ketoacidosis or hypoglycemia in a three-month phase 2 study.The company said it is on track to initiate the first pivotal study later this year.

For further details see:

vTv Therapeutics starts TTP399 diabetes study